Boston Partners Sells 65,272 Shares of Johnson & Johnson $JNJ

Boston Partners lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,694,023 shares of the company’s stock after selling 65,272 shares during the quarter. Boston Partners’ holdings in Johnson & Johnson were worth $259,017,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of JNJ. Brighton Jones LLC raised its position in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares in the last quarter. Wealth Group Ltd. purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $218,000. Smart Money Group LLC boosted its position in shares of Johnson & Johnson by 6.5% during the 1st quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock valued at $1,109,000 after acquiring an additional 407 shares during the last quarter. Bleakley Financial Group LLC grew its holdings in shares of Johnson & Johnson by 9.9% during the first quarter. Bleakley Financial Group LLC now owns 110,820 shares of the company’s stock worth $18,378,000 after purchasing an additional 10,025 shares in the last quarter. Finally, Gould Asset Management LLC CA increased its position in shares of Johnson & Johnson by 4.1% in the first quarter. Gould Asset Management LLC CA now owns 2,895 shares of the company’s stock worth $480,000 after purchasing an additional 115 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $193.76 on Wednesday. The company’s fifty day simple moving average is $184.79 and its two-hundred day simple moving average is $169.31. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The firm has a market cap of $466.83 billion, a PE ratio of 18.70, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. As a group, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s payout ratio is 50.19%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on JNJ shares. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Sanford C. Bernstein increased their target price on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Bank of America upped their price objective on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a report on Wednesday, October 15th. Finally, Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday, October 22nd. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.